摘要
Abstract
Objective To systematically evaluate the efficacy and safety of Astragalus Membranceus Injection versus Compound Danshen Injection in the treatment of angina pectoris.Methods Cochrane Library,EBase,PubMed,SCI,CBM,CNKI and VIP were retrieved by computer.According to the predefined inclusion and exclusion criteria,the trials were screened and the data were extracted.Then included Randomized Controlled Trials (RCT) were performed the methodological quality evaluation based on the Cochrane Handbook and the data were conducted the meta-analysis by using the RevMan software (version 5.1.6).Results 9 RCTs involving 839 patients were included.The meta-analysis results showed that the Astragalus Membranceus Injection group was superior to the Compound Danshen Injection group in the total effective rate [RR =1.19,95％ Cl (1.08,1.31),P =0.000 4],clinical symptoms [RR =1.23,95％ Cl (1.14,1.33),P ＜ 0.000 01] and electrocardiogram effective rate [RR=1.31,95％C1 (1.18,1.45),P ＜ 0.000 01].The differences between two groups had statistical significance.In addition,less adverse reactions were found in the Astragalus Membranceus Injection group [RR =0.17,95％ Cl (0.03,0.94),P =0.04].Conclusion The existing clinical studies reveal that Astragalus Membranceus Injection has better efficacy and higher safety in treating angina pectoris than Compound Danshen Injection.However,the evidence intensity of the included studies is not high and the sample size is relatively small,which may affect the result reliability,the conclusion needs to be confirmed by more precisely designed multi-center RCTs with large samples.关键词
冠心病/心绞痛/黄芪注射液/复方丹参注射液/Meta分析/系统评价Key words
coronary disease / angina pectoris / Astragalus Membranceus injection / Compound danshen injection / meta-analysis / systematic evaluation分类
医药卫生
